Positive Results

 
News Articles for Positive Results top ^
More Positive Results from Marathon's Rainbow and Sprite Zones: 1.80 g/t Au over 16.0 m and 1.37 g/t Au over 15.0 m Canada NewsWire TORONTO , Sept.
Sign-up for More Positive Results from Marathon's Rainbow and Sprite Zones: 1.80 g/t Au over 16.0 m and 1.37 g/t Au over 15.0 m investment picks
PARIS and TARRYTOWN, N.Y., July 9, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.
Sign-up for Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis investment picks
Results from Earlier Clinical Trials Published Today in the New England Journal of Medicine TARRYTOWN, N.Y. and PARIS , July 9, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi (EURONEXT: SAN and NYSE: SNY ) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.
Sign-up for Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis investment picks
2014/8/19
By Alex MacDonald LONDON--U.K.-listed pharmaceutical company AstraZeneca PLC (AZN.LN) said Tuesday it had positive results from its phase III studies of a new antibiotic treatment for hospitalized adult patients with complicated intra-abdominal infections.
Sign-up for AstraZeneca Sees Positive Results From CAZ-AVI Antibiotic Trial investment picks
Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology (ESMO) 2014 Congress investment picks
- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial - PARIS and TARRYTOWN, N.Y. , Aug.
Sign-up for Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 investment picks
Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in the ODYSSEY LONG TERM trial TARRYTOWN, New York and PARIS , Aug.
Sign-up for Regeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 investment picks
User Demand for Dario™ Demonstrated with Purchase Orders, Positive Initial Customer Feedback and Initial Revenue Generated CAESAREA, Israel , June 17, 2014 /PRNewswire/ -- LabStyle Innovations Corp.
Sign-up for LabStyle Innovations Reports Positive Results From the Initial Commercial Launch of Dario™ Smart Meter investment picks
2014/6/23
VANCOUVER , June 23, 2014 /PRNewswire/ - Pan American Silver Corp.
Sign-up for Pan American Silver Announces Positive Results for Dolores' Preliminary Economic Assessment investment picks
VANCOUVER , July 23, 2014 /PRNewswire/ - American CuMo Mining Corporation ("CuMoCo" or the "Company") (TSXV: MLY) (OTCQX: MLYCF) is very pleased to announce that Thomas Conway was elected as an additional director of the Company at the shareholder-requisitioned general meeting of shareholders of the Company held yesterday.
Sign-up for Positive results from shareholder meeting and appointment of new directors and officers investment picks
Phase 1-2a Clinical Trial Highlights: SANTA MONICA, Calif., Aug.
Sign-up for Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer Institute (NCI) investment picks
2014/8/19
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G020224-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/8/19/11G020224/Vivakor_logo-191968837290-787324512543.jpg IRVINE, CA--(Marketwired - August 19, 2014) - Vivakor Inc. (PINKSHEETS: VIVK) announced GAAP based financial results for the quarter ended June 30, 2014.
Sign-up for Vivakor Announces Solid 2nd Quarter 2014 Results and 5th Successive Quarter of Positive Results investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Positive Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Portfolio Update  |  Next: Positive Trends